253 related articles for article (PubMed ID: 28053292)
1. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.
Kumar NB; Pow-Sang J; Spiess PE; Park J; Salup R; Williams CR; Parnes H; Schell MJ
Oncotarget; 2016 Oct; 7(43):70794-70802. PubMed ID: 28053292
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.
Kumar NB; Pow-Sang J; Egan KM; Spiess PE; Dickinson S; Salup R; Helal M; McLarty J; Williams CR; Schreiber F; Parnes HL; Sebti S; Kazi A; Kang L; Quinn G; Smith T; Yue B; Diaz K; Chornokur G; Crocker T; Schell MJ
Cancer Prev Res (Phila); 2015 Oct; 8(10):879-87. PubMed ID: 25873370
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
Bettuzzi S; Brausi M; Rizzi F; Castagnetti G; Peracchia G; Corti A
Cancer Res; 2006 Jan; 66(2):1234-40. PubMed ID: 16424063
[TBL] [Abstract][Full Text] [Related]
4. Green tea catechins for chemoprevention of prostate cancer in patients with histologically-proven HG-PIN or ASAP. Concise review and meta-analysis.
Perletti G; Magri V; Vral A; Stamatiou K; Trinchieri A
Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577096
[TBL] [Abstract][Full Text] [Related]
5. Effect of green tea catechins in patients with high-grade prostatic intraepithelial neoplasia: Results of a short-term double-blind placebo controlled phase II clinical trial.
Micali S; Territo A; Pirola GM; Ferrari N; Sighinolfi MC; Martorana E; Navarra M; Bianchi G
Arch Ital Urol Androl; 2017 Oct; 89(3):197-202. PubMed ID: 28969404
[TBL] [Abstract][Full Text] [Related]
6. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.
Chow HH; Hakim IA; Vining DR; Crowell JA; Ranger-Moore J; Chew WM; Celaya CA; Rodney SR; Hara Y; Alberts DS
Clin Cancer Res; 2005 Jun; 11(12):4627-33. PubMed ID: 15958649
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals.
Chow HH; Cai Y; Hakim IA; Crowell JA; Shahi F; Brooks CA; Dorr RT; Hara Y; Alberts DS
Clin Cancer Res; 2003 Aug; 9(9):3312-9. PubMed ID: 12960117
[TBL] [Abstract][Full Text] [Related]
9. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
[TBL] [Abstract][Full Text] [Related]
10. ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer.
Lane JA; Er V; Avery KNL; Horwood J; Cantwell M; Caro GP; Crozier A; Smith GD; Donovan JL; Down L; Hamdy FC; Gillatt D; Holly J; Macefield R; Moody H; Neal DE; Walsh E; Martin RM; Metcalfe C
Cancer Prev Res (Phila); 2018 Nov; 11(11):687-696. PubMed ID: 30309839
[TBL] [Abstract][Full Text] [Related]
11. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.
Chow HH; Cai Y; Alberts DS; Hakim I; Dorr R; Shahi F; Crowell JA; Yang CS; Hara Y
Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):53-8. PubMed ID: 11205489
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.
Garcia FA; Cornelison T; Nuño T; Greenspan DL; Byron JW; Hsu CH; Alberts DS; Chow HH
Gynecol Oncol; 2014 Feb; 132(2):377-82. PubMed ID: 24388920
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.
Nguyen MM; Ahmann FR; Nagle RB; Hsu CH; Tangrea JA; Parnes HL; Sokoloff MH; Gretzer MB; Chow HH
Cancer Prev Res (Phila); 2012 Feb; 5(2):290-8. PubMed ID: 22044694
[TBL] [Abstract][Full Text] [Related]
15. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.
Kumar NB; Patel R; Pow-Sang J; Spiess PE; Salup R; Williams CR; Schell MJ
Oncotarget; 2017 Nov; 8(58):99093-99103. PubMed ID: 29228755
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets for green tea in prostate cancer prevention.
Adhami VM; Ahmad N; Mukhtar H
J Nutr; 2003 Jul; 133(7 Suppl):2417S-2424S. PubMed ID: 12840218
[TBL] [Abstract][Full Text] [Related]
17. Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements.
Dekant W; Fujii K; Shibata E; Morita O; Shimotoyodome A
Toxicol Lett; 2017 Aug; 277():104-108. PubMed ID: 28655517
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of the inhibitory effect of green tea catechins (GtCs) on prostate cancer progression in combination with molecular profiling of catechin-resistant tumors: an integrated view.
Bettuzzi S; Rizzi F; Belloni L
Pol J Vet Sci; 2007; 10(1):57-60. PubMed ID: 17388027
[TBL] [Abstract][Full Text] [Related]
19. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer.
Connors SK; Chornokur G; Kumar NB
Nutr Cancer; 2012; 64(1):4-22. PubMed ID: 22098273
[TBL] [Abstract][Full Text] [Related]
20. Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population.
Stingl JC; Ettrich T; Muche R; Wiedom M; Brockmöller J; Seeringer A; Seufferlein T
BMC Cancer; 2011 Aug; 11():360. PubMed ID: 21851602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
